E-mail a Wiley Online Library Link

Dieter Hoelzer CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia Cancer 119

Article first published online: 30 APR 2013 | DOI: 10.1002/cncr.28135

Inotuzumab ozogamicin achieves high response and molecular remission rates in patients with relapsed/refractory acute lymphoblastic leukemia with tolerable toxicity. It warrants further studies of inotuzumab in combination with chemotherapy or other targeted therapy.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

Choose captcha format: Image or Audio. Click here if you need help.